Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial. - Nie RC; Yuan SQ; Ding Y; Chen YM; Li YF; Liang CC; Cai MY; Chen GM; Wang W; Sun XW; Weng DS; Li DD; et al. (Signal transduction and targeted therapy, 2025)